Adalimumab in early axial spondyloarthritis (without radiological sacroiliitis): placebo controlled phase over 3 months followed by a 9 months open extension phase

Trial Profile

Adalimumab in early axial spondyloarthritis (without radiological sacroiliitis): placebo controlled phase over 3 months followed by a 9 months open extension phase

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Oct 2013 Results for patients whose disease flared over 5 years after treatment was stopped at week 52 presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 29 Jun 2009 Interim results presented at the 10th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top